Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Forms Strategic JV with Zhiyu Biomedicine, Contributing Oncology Antibody IP and ADC Platform for Multispecific Development

Fineline Cube Jun 8, 2026
Company Deals

Everest Medicines Licenses LNZ100 Presbyopia Treatment from Corxel for Greater China – Aceclidine-Based Eye Drop Offers Novel Miotic Mechanism

Fineline Cube Jun 8, 2026
Company Deals

SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying – Full IP Transfer in Category 2.2 and 2.3 Assets

Fineline Cube Jun 5, 2026
Company Deals

Lonza and Stipple Bio Forge Strategic ADC Partnership – Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies

Fineline Cube Jun 5, 2026
Company Deals

Gilead and Lakefront Complete $1.675B Acquisition of Ouro Medicines – Securing BCMAxCD3 T Cell Engager for Autoimmune Diseases

Fineline Cube Jun 5, 2026
Policy / Regulatory

China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development

Fineline Cube Jun 5, 2026
Company Drug

Bayer’s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial – First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population

Fineline Cube Jun 8, 2026
Company Drug

Novo Nordisk’s Zenagamtide (Amycretin) Delivers 1.71% A1C Reduction and 14.6% Weight Loss in Phase 2 Type 2 Diabetes Trial – Dual GLP-1/Amylin Agonist Advances to Phase 3

Fineline Cube Jun 8, 2026
Company Drug

CDE Signals Priority Review for Sanofi’s Dupixent and Other Drugs

Fineline Cube Feb 24, 2023

The Center for Drug Evaluation (CDE) website indicates that France major Sanofi’s (NASDAQ: SNY) Dupixent...

Company Drug

InnoCare and Keymed Announce First Dosing of ICP-B05 Clinical Study

Fineline Cube Feb 24, 2023

China-based firms InnoCare Pharma (HKG: 9969, SHA: 688428) and Keymed Biosciences (HKG: 2162) have jointly...

Company Drug

Luye Pharma’s Paliperidone Palmitate Approved for European Clinical Trials

Fineline Cube Feb 24, 2023

China-based Luye Pharma Group (HKG: 2186) has announced receiving clinical trial approval in Europe for...

Company Deals

Bio-Thera Solutions Partners with China Resource Medicine for Integrated Collaboration

Fineline Cube Feb 24, 2023

China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced a strategic partnership with compatriot firm China...

Company Medical Device

NMPA Approves STmed’s ECMO Product for Market

Fineline Cube Feb 24, 2023

The National Medical Products Administration (NMPA) has approved STmed Technology’s extracorporeal cardiopulmonary support auxiliary equipment...

Company Medical Device

Johnson & Johnson MedTech’s QDOT Catheter Approved in China for Atrial Fibrillation

Fineline Cube Feb 24, 2023

Johnson & Johnson MedTech’s next-generation QDOT micro diagnostic/ablation deflectable tip catheter, a disposable pressure monitoring...

Company Deals

Roche Returns Global Rights to Blueprint’s RET Inhibitor Gavreto

Fineline Cube Feb 24, 2023

US-based biotech Blueprint Medicines has announced that Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) has...

Company Deals

ConjuStar Peptide-Drug Conjugate Angel Financing

Fineline Cube Feb 24, 2023

Tianjin-based ConjuStar, a peptide-drug conjugate (PDC) developer incubated by Fosun Pharma and Wuxi Apptec, has...

Policy / Regulatory

Guangdong Adds Hospitals to GBA Drug and Device Green Channel

Fineline Cube Feb 23, 2023

The Health Commission of Guangdong Province (GDHC) has released a second list of designated medical...

Company Drug

Zai Lab to Present Zejula OS Study Results at ESMO Congress

Fineline Cube Feb 23, 2023

China-based Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) is set to present two oral presentations...

Company Deals

Huadong Medicine Expands Global Partnership with Scohia Pharma for SCO-094

Fineline Cube Feb 23, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) and Japanese firm Scohia Pharma Inc. have announced...

Company Drug

Zai Lab’s SUL-DUR NDA Accepted for Review by NMPA

Fineline Cube Feb 23, 2023

China-based Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has revealed that a New Drug Application...

Company Deals R&D

Changchun BCHT Biotechnology and IMB CAMS Enter Five-Year Research Pact

Fineline Cube Feb 23, 2023

China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced a five-year scientific research cooperation...

Company Deals

Lepu and Keymed License CLDN18.2 ADC CMG901 to AstraZeneca

Fineline Cube Feb 23, 2023

China-based firms Lepu Biopharma Co., Ltd (HKG: 2157) and Keymed Biosciences Inc. (HKG: 2162) have...

Company

Legend Biotech No Longer Faces Delisting from Nasdaq

Fineline Cube Feb 22, 2023

China-based Legend Biotech Corporation (NASDAQ: LEGN) has released a notice stating that it is no...

Company Drug

Abbisko’s ABSK121 Greenlit for Phase I Clinical Study by NMPA

Fineline Cube Feb 22, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced receiving the go-ahead from the...

Company Medical Device

MicroPort CardioFlow’s TAVI Product Approved in Thailand

Fineline Cube Feb 22, 2023

China-based MicroPort Scientific Corp’s (HKG: 0853) spin-off MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) has...

Company Deals

TransThera Biosciences Completes Series D+ Financing Round

Fineline Cube Feb 22, 2023

China’s Nanjing TransThera Sciences (Nanjing), Inc. has announced the completion of a Series D+ financing...

Company Drug

Shanghai Pharmaceuticals’ WST01 Receives FDA Clinical Clearance

Fineline Cube Feb 22, 2023

China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) has announced receiving clinical clearance from the...

Company Deals

Huahai Pharma Raises Funds for Digital Manufacturing and API Platform

Fineline Cube Feb 22, 2023

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) plans to raise RMB 1.56 billion (USD...

Posts pagination

1 … 572 573 574 … 679

Recent updates

  • Bayer’s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial – First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population
  • Novo Nordisk’s Zenagamtide (Amycretin) Delivers 1.71% A1C Reduction and 14.6% Weight Loss in Phase 2 Type 2 Diabetes Trial – Dual GLP-1/Amylin Agonist Advances to Phase 3
  • Oricell Therapeutics Receives NMPA Clearance for World’s First GPC3-Targeted CAR-T Therapy in Advanced Liver Cancer – Ori-C101 Enters Confirmatory Phase II
  • Boehringer Ingelheim’s Survodutide Dual Agonist Achieves 34% Visceral Fat Reduction and 60% MASLD Resolution in Phase III ADA 2026 Data
  • Eli Lilly’s Retatrutide Delivers Unprecedented 28.3% Weight Loss and Resolves Multiple Obesity Comorbidities in Phase III TRIUMPH-1 and TRANSCEND-T2D-1 Trials
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Bayer’s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial – First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population

Company Drug

Novo Nordisk’s Zenagamtide (Amycretin) Delivers 1.71% A1C Reduction and 14.6% Weight Loss in Phase 2 Type 2 Diabetes Trial – Dual GLP-1/Amylin Agonist Advances to Phase 3

Company Drug

Oricell Therapeutics Receives NMPA Clearance for World’s First GPC3-Targeted CAR-T Therapy in Advanced Liver Cancer – Ori-C101 Enters Confirmatory Phase II

Company Drug

Boehringer Ingelheim’s Survodutide Dual Agonist Achieves 34% Visceral Fat Reduction and 60% MASLD Resolution in Phase III ADA 2026 Data

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.